Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Atezolizumab in Combination With Carboplatin + Paclitaxel +Bevacizumab vs With Pemetrexed + Cisplatin or Carboplatin With Stage IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER With EGFR(+) or ALK(+)

NCT03991403 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT03991403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03991403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Atezolizumab in Combination With Carboplatin + Paclitaxel +Bevacizumab vs With Pemetrexed + Cisplatin or Carboplatin With Stage IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER With EGFR(+) or ALK(+)
Lead sponsor
Samsung Medical Center
Phase
Phase 3
Overall status
Unknown status
Start date
August 27, 2019
Completion date
March 11, 2024
Enrollment
228 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer